文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis.

作者信息

Burdeynaya Anna L, Afanasieva Olga I, Ezhov Marat V, Klesareva Elena A, Saidova Marina A, Pokrovsky Sergey N

机构信息

Laboratory of Lipid Disorders, Department of Atherosclerosis, A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.

Laboratory of Atherosclerosis, Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.

出版信息

Diseases. 2023 Mar 3;11(1):43. doi: 10.3390/diseases11010043.


DOI:10.3390/diseases11010043
PMID:36975592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10047835/
Abstract

Aortic valve stenosis is the most common valvular heart disease in the Western world. Lipoprotein(a) (Lp(a)) is an independent risk factor of coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS). The aim of this study was to assess the role of Lp(a) and its autoantibodies [autoAbs] in CAVS in patients with and without CHD. We included 250 patients (mean age 69 ± 3 years, males 42%) and divided them into three groups. There were two groups of patients with CAVS depending on the presence (group 1) or absence of CHD (group 2). The control group included the patients without CHD or CAVS. According to logistic regression analysis, levels of Lp(a), IgM autoAbs to oxidized Lp(a) (oxLp(a)), and age were independent predictors of CAVS. A concomitant increase in Lp(a) level (≥30 mg/dL) and a decrease in IgM autoAbs concentration (<9.9 lab. Units) are associated with CAVS with an odds ratio (OR) of 6.4, < 0.01, and with CAVS and CHD with an OR of 17.3, < 0.001. IgM autoantibodies to oxLp(a) are associated with calcific aortic valve stenosis regardless of Lp(a) concentration and other risk factors. Higher Lp(a) and lower IgM autoantibodies to oxLp(a) levels are associated with a much higher risk of calcific aortic valve stenosis.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/c574702f2921/diseases-11-00043-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/ae12d6037942/diseases-11-00043-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/65eeff28675e/diseases-11-00043-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/c574702f2921/diseases-11-00043-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/ae12d6037942/diseases-11-00043-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/65eeff28675e/diseases-11-00043-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f8/10047835/c574702f2921/diseases-11-00043-g003.jpg

相似文献

[1]
Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis.

Diseases. 2023-3-3

[2]
Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification.

JAMA Cardiol. 2019-7-1

[3]
Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.

J Intern Med. 2016-5-30

[4]
Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.

Atherosclerosis. 2017-5

[5]
Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis.

JACC Basic Transl Sci. 2020-8-26

[6]
Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.

JAMA Cardiol. 2018-12-1

[7]
The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting.

Angiology. 2017-10

[8]
Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans.

Heart. 2020-9

[9]
Plasma Lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period.

Atherosclerosis. 2022-5

[10]
Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis.

Metabolites. 2021-7-16

引用本文的文献

[1]
Correlation between circulating lipoprotein(a) levels and cardiovascular events risk in patients with type 2 diabetes.

Heliyon. 2024-9-4

本文引用的文献

[1]
Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease.

J Cardiovasc Dev Dis. 2021-1-27

[2]
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation. 2021-2-2

[3]
Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review.

Front Immunol. 2020-9-10

[4]
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.

JAMA Cardiol. 2020-6-1

[5]
Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy.

Cardiol Clin. 2019-11-1

[6]
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020-1-1

[7]
Vaccination against atherosclerosis: An overview.

Hellenic J Cardiol. 2020

[8]
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

J Am Coll Cardiol. 2019-6-25

[9]
Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week.

J Am Coll Cardiol. 2018-10-23

[10]
Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.

Atherosclerosis. 2017-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索